What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.”In the company’s words, NCT06714513 on ClinicalTrials.gov
- Tested for
- Tuberculosis, Pulmonary
- Main trialPhase 1
- “The purpose of this study is to evaluate the safety and explore the immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in the Bacillus Calmette-Guérin (BCG)-vaccinated older adults aged 55 to 74 with negative or positive result on the QuantiFERON-TB (QFT) test. Eligible participants will be randomly assigned based on age group and the QFT test results to receive either QTP101 (Dose 1 and Dose 2) or placebo. Safety and immunogenicity will be monitored from the first dose until 12 months after the final dose of the…”In the company’s words, NCT06714513 on ClinicalTrials.gov
Other drugs for Tuberculosis, Pulmonary
- SudapyridineShanghai Jiatan Pharmatech Co., Ltd · Phase 3
- RESP30TBThirty Respiratory Limited · Phase 2
Coming up1
- DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Dec 2026 | ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026